ClinicalTrials.gg
RecruitingNCT05519735LOMIUpdated May 25, 2023

Lymphatic Organs and Myocardium After Myocardial Infarction

An interventional study of Multimodality Imaging in Myocardial Infarction, Myocardial Injury and Myocardial Inflammation, sponsored by Wuerzburg University Hospital. Recruiting at 2 sites in Germany. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2023-05-25.

Sponsored by Wuerzburg University Hospital · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Registered 4 months after the study started (first participant enrolled Apr 2022, registered Aug 2022).
  • Started Apr 2022; still recruiting 4 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
57
Allocation
Not applicable
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 159 studies in Myocardial Infarction with a site in Germany — 13 open to participants now, 17 under way, 5 of them phase 3. Myocardial Infarction · Germany.

Planned enrollment
93rd of 107
57 · median 429
Started
2022
with 3 others
No phase
24 of 159
5 open now
Primary completion
2025-12
later than 1 of 16 live
Registered
143rd of 159
by date

Among the 159 studies in Myocardial Infarction with a site in Germany, this one is the 93rd largest by planned enrollment of the 107 interventional ones that give a count, is one of 4 that started in 2022, is one of 24 with no phase, reaches primary completion later than 1 of the 16 other live ones, and was the 143rd registered.

Myocardial Infarction

2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.

Browse Myocardial Infarction studies →

Open to participants now

13 of the 159 studies in Myocardial Infarction with a site in Germany are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 159 studies in Myocardial Infarction with a site in Germany, or all of them as a file.
02

Study summary

The adaptive immune response plays an important role in myocardial healing and remodeling after acute myocardial infarction in patients. Therefore, the involved lymphocytes represent a novel target for therapeutic interventions. However, there are no established blood-derived biomarkers to predict the quantity and quality of the adaptive immune response to cardiac injury. Multimodal imaging of the heart and immunologic organs might provide such information.

Recent retrospective analysis of patients after MI revealed enlarged mediastinal lymph nodes associated with increased CXCR4 radiotracer accumulation, thereby indicating that CXCR4 PET-based lymph node imaging provides a non-invasive quantitative readout of the local adaptive immune response. These considerations are further fuelled by the fact that, within lymph nodes, CXCR4 is expressed almost exclusively on lymphocytes, whereas various other cell types express CXCR4 within the myocardium.

This leads to the hypothesis that the size of mediastinal lymph nodes and their respective CXCR4 PET signals correlate with the adaptive immune response to cardiac injury and might provide predictive information for functional cardiac decline during follow-up.

This prospective clinical study will use multimodal imaging to monitor chemokine receptor 4 (CXCR4) expression in the lymph nodes, myocardium, spleen, and bone marrow after acute MI. The combination of cardiac magnetic resonance (CMR), echocardiography, and positron emission tomography (PET) along with blood collection for immunophenotyping will allow to determine i) if the size of mediastinal lymph nodes and their respective PET-derived CXCR4 signals at baseline correlate with the adaptive immune response to acute cardiac injury; and ii) if they predict cardiac adverse remodelling during longitudinal follow-up.

03

Conditions studied

  • Myocardial Infarction
  • Myocardial Injury
  • Myocardial Inflammation

Keywords

  • CXCR4
  • CMR
  • Lymphatic organs
  • Myocardial Infarction
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients with acute myocardial infarction (STEMI) who were treated with immediate catheterization
  • stable clinical course
  • male/female, above 18 years old

Exclusion criteria

Exclusion Criteria:

  • hemodynamic instablity > 48 h after immediate catherization
  • known CAD
  • known structural heart disease
  • multi vessel disease
  • NSTEMI
  • sarcoidosis
  • therapy
  • acute inflammatory disease
  • no consent obtainable
  • contraindiations for CMR
  • impaired renal function
  • active cardiac implants, ferromagnetic implants
  • pregnancy, breast-feeding
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
57 participants (estimated)

Study arms

  • Other
    Multimodal imaging

    Multimodal imaging approach. This includes a CXCR4 targeted PET/CT (\[68Ga\]Pentixafor) during the acute hospital stay, and serial CMR and Echo imaging.

    Diagnostic Test: Multimodality Imaging

Interventions

  • Diagnostic testMultimodality Imaging

    Patients receive CXCR4-targeted PET/CT, CMR and Echo

06

What researchers measure

Primary outcomes

  1. CXCR4 PET-derived uptake after myocardial infarction

    Semi-quantitative assessment of CXCR4-derived radiotracer accumulation in the myocardium, mediastinal lymph nodes, bone marrow and spleen in patients after myocardial infarction. For quantitative analysis, standardized uptake values (SUV) will be calculated in organs of interest.

    Time frame: 12 months

Secondary outcomes

  1. Correlation of quantitative parameters (SUV) with peripheral lymphocytes

    SUV of organs of interest are correlated to the phenotype of peripheral lymphocytes in the peripheral blood after myocardial infarction.

    Time frame: 12 months

  2. Time course of SUV after myocardial infarction

    PET/CT scans for each patient will be allocated to either day 3-4 or day 5-8 after myocardial infarction. SUV of organs of interest will be correlated to time point of imaging.

    Time frame: 12 months

  3. Correlation of myocardial damage to SUV

    CMR will determine the extend of myocardial damage as necrotic volume, volume of MVO and myocardial edema. These findings will be correlated to SUV.

    Time frame: 12 months

  4. Correlation of SUV with the clincial course

    Myocardial function (LVEF) and scar volumes as determined by CMR will be correlated to the intital SUV in order to correlate the clinical outcome to the tracer activity.

    Time frame: 12 months

07

Study locations

2 of 2 sites recruiting
  • University Hospital Wuerzburg
    Wuerzburg, 97080, Germany
    Recruiting
  • Klinikum Würzburg Mitte, Medizinische Klinik
    Würzburg, 97070, Germany
    Recruiting
    • Willibald Hochholzer, Professor · Contact
    • · Contact+49 931 7910
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2022 (actual). Primary completion is estimated for Dec 2025, 44 months after the start.

Of 322 non-industry interventional studies with no phase under Myocardial Infarction, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 58. This study's planned 44 months is above that.

Counting every sponsor, half of 355 studies reached it within 34 months; a quarter within 15 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2022
First posted
Aug 29, 2022
StartActual
Apr 1, 2022
Primary completionEst.
Dec 2025
CompletionEst.
Dec 2026
Last update
May 25, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 25, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05519735
Lead sponsor
Wuerzburg University Hospital
Responsible party
Theresa Reiter (Principal Investigator, Wuerzburg University Hospital) — Principal investigator
First posted
Aug 29, 2022
Start date
Apr 1, 2022
Primary completion
Dec 2025 (estimated)
Completion
Dec 2026 (estimated)
Last update
May 25, 2023

Study contacts

Theresa Reiter, MD
Contact
reiter_t@ukw.de
+4993120139944
Rudolf Werner, MD
Contact
werner_r1@ukw.de
+4993120135906
Theresa Reiter, MD
principal investigator · Wuerzburg University Hospital
Rudolf Werner, MD
principal investigator · Wuerzburg University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion